Biomarkers along the continuum of care in lung cancer
Blood-based biomarkers are valuable diagnostic tools for the management of lung cancer patients. They support not only differential diagnosis and histological subtyping, but are also applied for estimation of prognosis, stratification for specific therapies, monitoring of therapy response, surveilla...
Saved in:
| Published in: | Scandinavian journal of clinical & laboratory investigation. Supplement Vol. 76; no. 45; pp. S40 - S45 |
|---|---|
| Main Author: | |
| Format: | Journal Article |
| Language: | English |
| Published: |
Norway
Taylor & Francis
13.07.2016
|
| Subjects: | |
| ISSN: | 0036-5513, 2166-1030, 1502-7686, 2166-1030 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Blood-based biomarkers are valuable diagnostic tools for the management of lung cancer patients. They support not only differential diagnosis and histological subtyping, but are also applied for estimation of prognosis, stratification for specific therapies, monitoring of therapy response, surveillance monitoring and early detection of residual or progressive disease. Early diagnosis of lung cancer in high risk populations (screening) is a promising future indication but poses high medical and economic challenges to marker performance. The five mostly used classical 'tumor markers' show characteristic profiles of sensitivity and specificity for non-small cell lung cancer (NSCLC) like cytokeratin 19-fragments (CYFRA 21-1), carcino-embryonic antigen (CEA) and squamous cancer cell antigen (SCCA) as well as for small cell lung cancer (SCLC) like progastrin-releasing peptide (ProGRP) and neuron-specific enolase (NSE). Combined use and pattern recognition approaches enable highly accurate diagnosis, subtyping and therapy monitoring. For the interpretation of serial measurements on an individual level, marker-specific algorithms have to be developed. So-called companion diagnostics identify druggable molecular changes in signaling pathways of tumor tissue that can be addressed by targeted therapies. New highly sensitive technologies enable the convenient and serial molecular characterization on circulating tumor DNA (ctDNA) in the blood, too. This approach is helpful when biopsies are not available and to overcome tumor molecular heterogeneity and plasticity. As only a portion of patients have such druggable molecular changes, future strategies will imply the combined use of classical and new ctDNA-based biomarkers to optimize the management of lung cancer patients during the course of disease. |
|---|---|
| AbstractList | Blood-based biomarkers are valuable diagnostic tools for the management of lung cancer patients. They support not only differential diagnosis and histological subtyping, but are also applied for estimation of prognosis, stratification for specific therapies, monitoring of therapy response, surveillance monitoring and early detection of residual or progressive disease. Early diagnosis of lung cancer in high risk populations (screening) is a promising future indication but poses high medical and economic challenges to marker performance. The five mostly used classical 'tumor markers' show characteristic profiles of sensitivity and specificity for non-small cell lung cancer (NSCLC) like cytokeratin 19-fragments (CYFRA 21-1), carcino-embryonic antigen (CEA) and squamous cancer cell antigen (SCCA) as well as for small cell lung cancer (SCLC) like progastrin-releasing peptide (ProGRP) and neuron-specific enolase (NSE). Combined use and pattern recognition approaches enable highly accurate diagnosis, subtyping and therapy monitoring. For the interpretation of serial measurements on an individual level, marker-specific algorithms have to be developed. So-called companion diagnostics identify druggable molecular changes in signaling pathways of tumor tissue that can be addressed by targeted therapies. New highly sensitive technologies enable the convenient and serial molecular characterization on circulating tumor DNA (ctDNA) in the blood, too. This approach is helpful when biopsies are not available and to overcome tumor molecular heterogeneity and plasticity. As only a portion of patients have such druggable molecular changes, future strategies will imply the combined use of classical and new ctDNA-based biomarkers to optimize the management of lung cancer patients during the course of disease.Blood-based biomarkers are valuable diagnostic tools for the management of lung cancer patients. They support not only differential diagnosis and histological subtyping, but are also applied for estimation of prognosis, stratification for specific therapies, monitoring of therapy response, surveillance monitoring and early detection of residual or progressive disease. Early diagnosis of lung cancer in high risk populations (screening) is a promising future indication but poses high medical and economic challenges to marker performance. The five mostly used classical 'tumor markers' show characteristic profiles of sensitivity and specificity for non-small cell lung cancer (NSCLC) like cytokeratin 19-fragments (CYFRA 21-1), carcino-embryonic antigen (CEA) and squamous cancer cell antigen (SCCA) as well as for small cell lung cancer (SCLC) like progastrin-releasing peptide (ProGRP) and neuron-specific enolase (NSE). Combined use and pattern recognition approaches enable highly accurate diagnosis, subtyping and therapy monitoring. For the interpretation of serial measurements on an individual level, marker-specific algorithms have to be developed. So-called companion diagnostics identify druggable molecular changes in signaling pathways of tumor tissue that can be addressed by targeted therapies. New highly sensitive technologies enable the convenient and serial molecular characterization on circulating tumor DNA (ctDNA) in the blood, too. This approach is helpful when biopsies are not available and to overcome tumor molecular heterogeneity and plasticity. As only a portion of patients have such druggable molecular changes, future strategies will imply the combined use of classical and new ctDNA-based biomarkers to optimize the management of lung cancer patients during the course of disease. Blood-based biomarkers are valuable diagnostic tools for the management of lung cancer patients. They support not only differential diagnosis and histological subtyping, but are also applied for estimation of prognosis, stratification for specific therapies, monitoring of therapy response, surveillance monitoring and early detection of residual or progressive disease. Early diagnosis of lung cancer in high risk populations (screening) is a promising future indication but poses high medical and economic challenges to marker performance. The five mostly used classical 'tumor markers' show characteristic profiles of sensitivity and specificity for non-small cell lung cancer (NSCLC) like cytokeratin 19-fragments (CYFRA 21-1), carcino-embryonic antigen (CEA) and squamous cancer cell antigen (SCCA) as well as for small cell lung cancer (SCLC) like progastrin-releasing peptide (ProGRP) and neuron-specific enolase (NSE). Combined use and pattern recognition approaches enable highly accurate diagnosis, subtyping and therapy monitoring. For the interpretation of serial measurements on an individual level, marker-specific algorithms have to be developed. So-called companion diagnostics identify druggable molecular changes in signaling pathways of tumor tissue that can be addressed by targeted therapies. New highly sensitive technologies enable the convenient and serial molecular characterization on circulating tumor DNA (ctDNA) in the blood, too. This approach is helpful when biopsies are not available and to overcome tumor molecular heterogeneity and plasticity. As only a portion of patients have such druggable molecular changes, future strategies will imply the combined use of classical and new ctDNA-based biomarkers to optimize the management of lung cancer patients during the course of disease. |
| Author | Holdenrieder, Stefan |
| Author_xml | – sequence: 1 givenname: Stefan surname: Holdenrieder fullname: Holdenrieder, Stefan email: Holdenrieder@dhm.mhn.de organization: Institute of Laboratory Medicine, German Heart Center of the Technical University Munich |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/27542002$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkDtPwzAYRS0Eog_4CaCMLCl-JxELUPGSKrF0txzHBkNiFzsR6r_HUduFAQbLsnzu9-meGTh23mkALhBcIFjCawgJZwyRBYaILxCGJaX8CEwRgzgveMmPwXRk8hGagFmMHzC9SUlPwQQXjGII8RSwe-s7GT51iJlsvXvL-nedKe9664ahy7zJlAw6sy5rh_SrpFM6nIETI9uoz_f3HKwfH9bL53z1-vSyvFvlinDe5wWkxOiaNFKpBlcF0rQoS8JUgRmtDJWKUC2hMkxRXnNpcENYIWtWjUeTObjajd0E_zXo2IvORqXbVjrthyhQiQjHFa5QQi_36FB3uhGbYFOtrTg0TcDNDlDBxxi0Ecr2srepaZC2FQiK0as4eBWjV7H3mtLsV_qw4L_c7S5nnfGhk98-tI3o5bb1wYTk0kZB_h7xA4TRjOY |
| CitedBy_id | crossref_primary_10_1016_j_cca_2018_09_015 crossref_primary_10_1111_crj_13815 crossref_primary_10_1111_crj_70027 crossref_primary_10_2174_0115701646331003240821061517 crossref_primary_10_3233_TUB_240005 crossref_primary_10_1016_j_currproblcancer_2020_100584 crossref_primary_10_1016_j_lungcan_2024_107477 crossref_primary_10_1002_ctm2_367 crossref_primary_10_1097_CM9_0000000000002991 crossref_primary_10_1038_s41379_018_0019_5 crossref_primary_10_3233_TUB_230015 crossref_primary_10_1186_s12967_019_1828_0 crossref_primary_10_3233_TUB_230014 crossref_primary_10_1016_j_lungcan_2021_09_008 crossref_primary_10_1080_1354750X_2017_1419284 crossref_primary_10_1177_1753466620910092 crossref_primary_10_1016_j_canrad_2019_07_160 crossref_primary_10_1002_psp4_12937 crossref_primary_10_1038_s41598_017_07915_0 crossref_primary_10_1007_s00330_021_08277_y crossref_primary_10_1007_s13300_017_0356_2 crossref_primary_10_3233_TUB_230021 crossref_primary_10_1016_j_pharmthera_2021_107917 crossref_primary_10_3233_TUB_211504 crossref_primary_10_3390_cancers11070923 crossref_primary_10_3233_TUB_230006 crossref_primary_10_1016_j_jprot_2024_105247 crossref_primary_10_1080_1354750X_2024_2360038 crossref_primary_10_1177_03936155221099036 crossref_primary_10_1111_crj_70051 |
| Cites_doi | 10.1373/clinchem.2015.242453 10.1158/1078-0432.CCR-08-0678 10.3322/caac.21348 10.3233/CBM-2009-0129 10.1002/ijc.29210 10.3233/CBM-2009-0127 10.1515/CCLM.2011.694 10.1007/s13277-012-0379-2 10.2217/fon.14.21 10.3233/CBM-2009-0128 10.1038/nrclinonc.2013.110 10.1126/scitranslmed.3007094 10.3322/caac.21332 10.1016/j.lungcan.2011.12.012 10.1373/clinchem.2014.222679 10.3233/CBM-2009-0130 10.1002/cncr.22330 10.1016/j.cca.2014.09.015 10.1159/000224628 10.1200/JCO.2012.45.2011 |
| ContentType | Journal Article |
| Copyright | 2016 Medisinsk Fysiologisk Forenings Forlag (MFFF) 2016 |
| Copyright_xml | – notice: 2016 Medisinsk Fysiologisk Forenings Forlag (MFFF) 2016 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1080/00365513.2016.1208446 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Anatomy & Physiology |
| EISSN | 1502-7686 2166-1030 |
| EndPage | S45 |
| ExternalDocumentID | 27542002 10_1080_00365513_2016_1208446 1208446 |
| Genre | Article Journal Article Review |
| GroupedDBID | --- -~X 00X 03L 0R~ 123 36B 4.4 53G 5RE AAGDL AALUX AAMIU AAPUL AAPXX AAQRR AAWTL ABBKH ABDBF ABEIZ ABJNI ABLIJ ABLJU ABLKL ABOCM ABUPF ABWVI ABXYU ACENM ACGEJ ACGFS ACIEZ ACUHS ADCVX ADRBQ ADXPE AECIN AENEX AEOZL AFKVX AFRVT AGDLA AGFJD AGRBW AGYJP AIJEM AIRBT AJWEG AKBVH ALMA_UNASSIGNED_HOLDINGS ALQZU ALYBC AMDAE AQTUD BABNJ BLEHA BOHLJ CCCUG COF CS3 DKSSO DU5 EAP EAS EBB EBC EBD EBS EBX EHN EJD EMB EMK EMOBN EPL EPT ESX F5P H13 HZ~ KRBQP KSSTO KWAYT KYCEM L7B M4Z O9- P2P Q~Q RNANH RVRKI SV3 TASJS TBQAZ TDBHL TERGH TFDNU TFL TFW TUROJ TUS UEQFS UHWXJ V1S WH7 ~1N AAYXX CITATION .55 .GJ 04C 3O- AAQQT ADBBV AFFNX BMSDO CGR CUY CVF ECM EIF EIHBH MK0 NPM OVD TEORI X7M ZGI ZXP 7X8 |
| ID | FETCH-LOGICAL-c366t-7043feb3daccd2971e478835c72549f4ac34ea0cf5c46b6af2d357ab59ab59e3 |
| IEDL.DBID | TFW |
| ISICitedReferencesCount | 28 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000383110200010&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0036-5513 2166-1030 |
| IngestDate | Fri Jul 11 10:39:42 EDT 2025 Wed Feb 19 01:57:14 EST 2025 Sat Nov 29 02:41:40 EST 2025 Tue Nov 18 22:13:34 EST 2025 Mon Oct 20 23:42:58 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 45 |
| Keywords | lung cancer liquid profiling diagnosis Biomarker serum personalized medicine |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c366t-7043feb3daccd2971e478835c72549f4ac34ea0cf5c46b6af2d357ab59ab59e3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| PMID | 27542002 |
| PQID | 1813629291 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_1813629291 pubmed_primary_27542002 crossref_primary_10_1080_00365513_2016_1208446 informaworld_taylorfrancis_310_1080_00365513_2016_1208446 crossref_citationtrail_10_1080_00365513_2016_1208446 |
| PublicationCentury | 2000 |
| PublicationDate | 2016-07-13 |
| PublicationDateYYYYMMDD | 2016-07-13 |
| PublicationDate_xml | – month: 07 year: 2016 text: 2016-07-13 day: 13 |
| PublicationDecade | 2010 |
| PublicationPlace | Norway |
| PublicationPlace_xml | – name: Norway |
| PublicationTitle | Scandinavian journal of clinical & laboratory investigation. Supplement |
| PublicationTitleAlternate | Scand J Clin Lab Invest Suppl |
| PublicationYear | 2016 |
| Publisher | Taylor & Francis |
| Publisher_xml | – name: Taylor & Francis |
| References | CIT0012 Molina R (CIT0010) 2010; 6 Holdenrieder S (CIT0011) 2010; 6 CIT0016 Holdenrieder S (CIT0014) 2010; 6 CIT0015 CIT0017 Stieber P (CIT0009) 2008; 32 Holdenrieder S. (CIT0018) 2014 CIT0019 Barak V (CIT0013) 2010; 6 CIT0021 CIT0020 CIT0001 CIT0023 CIT0022 Gruber C (CIT0008) 2008; 32 CIT0003 CIT0025 CIT0002 CIT0024 CIT0005 CIT0004 CIT0007 CIT0006 |
| References_xml | – start-page: 309 volume-title: Circulating nucleic acids in early diagnosis, prognosis and treatment monitoring, advances in predictive, preventive and personalised medicine 5 year: 2014 ident: CIT0018 – ident: CIT0024 doi: 10.1373/clinchem.2015.242453 – ident: CIT0020 doi: 10.1158/1078-0432.CCR-08-0678 – ident: CIT0002 doi: 10.3322/caac.21348 – volume: 32 start-page: 339 year: 2008 ident: CIT0009 publication-title: J Lab Med – volume: 6 start-page: 191 year: 2010 ident: CIT0013 publication-title: Cancer Biomark doi: 10.3233/CBM-2009-0129 – ident: CIT0001 doi: 10.1002/ijc.29210 – volume: 6 start-page: 163 year: 2010 ident: CIT0010 publication-title: Cancer Biomark doi: 10.3233/CBM-2009-0127 – ident: CIT0015 doi: 10.1515/CCLM.2011.694 – ident: CIT0017 doi: 10.1007/s13277-012-0379-2 – ident: CIT0005 doi: 10.2217/fon.14.21 – volume: 6 start-page: 179 year: 2010 ident: CIT0011 publication-title: Cancer Biomark doi: 10.3233/CBM-2009-0128 – ident: CIT0012 doi: 10.1038/nrclinonc.2013.110 – ident: CIT0006 – ident: CIT0004 – ident: CIT0023 doi: 10.1126/scitranslmed.3007094 – ident: CIT0003 doi: 10.3322/caac.21332 – ident: CIT0021 doi: 10.1016/j.lungcan.2011.12.012 – ident: CIT0025 doi: 10.1373/clinchem.2014.222679 – volume: 6 start-page: 197 year: 2010 ident: CIT0014 publication-title: Cancer Biomark doi: 10.3233/CBM-2009-0130 – ident: CIT0019 doi: 10.1002/cncr.22330 – ident: CIT0016 doi: 10.1016/j.cca.2014.09.015 – ident: CIT0007 doi: 10.1159/000224628 – volume: 32 start-page: 361 year: 2008 ident: CIT0008 publication-title: J Lab Med – ident: CIT0022 doi: 10.1200/JCO.2012.45.2011 |
| SSID | ssj0003384 ssj0026105 |
| Score | 2.266474 |
| SecondaryResourceType | review_article |
| Snippet | Blood-based biomarkers are valuable diagnostic tools for the management of lung cancer patients. They support not only differential diagnosis and histological... |
| SourceID | proquest pubmed crossref informaworld |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | S40 |
| SubjectTerms | Antigens, Neoplasm - blood Antigens, Neoplasm - genetics Antineoplastic Agents - therapeutic use Biomarker Biomarkers, Tumor - blood Biomarkers, Tumor - genetics Carcinoembryonic Antigen - blood Carcinoembryonic Antigen - genetics diagnosis DNA, Neoplasm - blood DNA, Neoplasm - genetics Early Diagnosis Gene Expression Regulation, Neoplastic Humans Keratin-19 - blood Keratin-19 - genetics liquid profiling lung cancer Lung Neoplasms - diagnosis Lung Neoplasms - drug therapy Lung Neoplasms - genetics Lung Neoplasms - pathology Peptide Fragments - blood Peptide Fragments - genetics personalized medicine Phosphopyruvate Hydratase - blood Phosphopyruvate Hydratase - genetics Prognosis Recombinant Proteins - blood Recombinant Proteins - genetics Serpins - blood Serpins - genetics serum Transcriptome Treatment Outcome |
| Title | Biomarkers along the continuum of care in lung cancer |
| URI | https://www.tandfonline.com/doi/abs/10.1080/00365513.2016.1208446 https://www.ncbi.nlm.nih.gov/pubmed/27542002 https://www.proquest.com/docview/1813629291 |
| Volume | 76 |
| WOSCitedRecordID | wos000383110200010&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAWR databaseName: Taylor & Francis Online Journals customDbUrl: eissn: 1502-7686 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0026105 issn: 0036-5513 databaseCode: TFW dateStart: 19510101 isFulltext: true titleUrlDefault: https://www.tandfonline.com providerName: Taylor & Francis – providerCode: PRVAWR databaseName: Taylor & Francis Online Journals customDbUrl: eissn: 1502-7686 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0003384 issn: 0036-5513 databaseCode: TFW dateStart: 19490101 isFulltext: true titleUrlDefault: https://www.tandfonline.com providerName: Taylor & Francis |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV05T8MwFLagQoiF-yhHZSTWVE7s2PEIiIoBKoYKukWOE6NKJUE5-P345Sh0qDrAkMHDy_H8_A77y_cQuiFGcuFp4mhJjC1Q4sBRHjUO91hkar6Wmo7h9UmMx8F0Kl9aNGHRwiqhhjYNUUTtq2Fxq6joEHHQf4xDXxIAZvGh65HA1jTWC9vMHmx8Mnpb-GJbgLGOdhdEun94Vt1lKTotcZeuzkDrSDTa-4dv2Ee7bRqKbxu7OUAbSXqItp_bg_Yj5N_Nsg9A7uQFVvMsfcc2UcSAa5-lVfWBM4MBM4ZnKZ5bd2EH1njyYzQZPUzuH522w4KjKeelIwijxpbTsdI69qRwE2DTp74WUDcapjRliSLa-JrxiCvjxdQXKvIlXAk9Qb00S5MzhH03EkRSzaSImXK59KkQmvOIRoYSxfuIdYoNdcs-Dk0w5qH7Q1JaayQEjYStRvpouBD7bOg31gnI37MWlvW-h2malIR0jex1N8WhXWRwcqLSJKuK0KZBNtDbTNLto9Nm7hev40EPYRtXzv_w5Au0A0PYM3bpJeqVeZVcoS39Vc6KfIA2xTQY1Ib9DV8O7fA |
| linkProvider | Taylor & Francis |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3JTsMwEB2xCbiwL2U1EtegJHbs-giICkTpqQJuluPEqFJJUJvy_XiylPaAOMAhhyiaJB4vs_j5DcClbyUXofE9I33rApSk7emQWo-HLLYlX0tJx_DcFb1e-_VVzp6FQVglxtC2Iooo12qc3JiMbiBxWICMY2ESRGbxqyD02y6oWYTlyNlahPX1Oy_T1diFYKwh3kWZ5hTPT6-Zs09z7KU_-6ClLeps_kcrtmCj9kTJdTV0tmEhzXZg9anea9-F6GaQvyN4ZzQmephnb8T5igSh7YNsMnknuSUIGyODjAzdiuFu3PgZ7UG_c9e_vffqIgueoZwXnvAZtS6iTrQxSShFkCKhPo2MwNDRMm0oS7VvbGQYj7m2YUIjoeNI4pXSfVjK8iw9BBIFsfAlNUyKhOmAy4gKYTiPaWypr3kLWKNZZWoCcqyDMVTBN09pqRGFGlG1RlpwNRX7qBg4fhOQs92mijL1Yas6JYr-InvR9LFy8ww3T3SW5pOxcp6Qs_XOmQxacFB1_vR3Qiwj7EzL0R--fA5r9_2nruo-9B6PYR0fYQo5oCewVIwm6SmsmM9iMB6dleP7C9Jh8Sk |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3JTsMwEB2xCXFhX8pqJK5BSezY9ZGtAgEVhwq4WY4To0ptUjUt348nS4ED4gCHHKJossyMPTP2yxuAM99KLkLje0b61hUoSdvTIbUeD1lsS76Wko7h-UF0u-3XV_lUowmLGlaJNbStiCLKuRoH9yixDSIO-49x7EuCwCx-HoR-29U087BYkmM5l-51XmaTsavAWMO7izLNTzw_3eZbePpGXvpzClqGos7aP3zEOqzWeSi5qBxnA-bSbBOWH-ud9i2ILvv5EKE744LoQZ69EZcpEgS297PpdEhySxA0RvoZGbj5wp047xlvQ69z07u69eoWC56hnE884TNqXT2daGOSUIogRTp9GhmBhaNl2lCWat_YyDAec23DhEZCx5HEI6U7sJDlWboHJApi4UtqmBQJ0wGXERXCcB7T2FJf8xawRrHK1PTj2AVjoIJPltJSIwo1omqNtOB8Jjaq-Dd-E5BfraYm5cKHrbqUKPqL7GljYuVGGW6d6CzNp4VyeZCL9C6VDFqwW9l-9johNhF2gWX_D08-geWn6456uOveH8AKXsH144AewsJkPE2PYMm8T_rF-Lj07g_NTu_N |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Biomarkers+along+the+continuum+of+care+in+lung+cancer&rft.jtitle=Scandinavian+journal+of+clinical+%26+laboratory+investigation.+Supplement&rft.au=Holdenrieder%2C+Stefan&rft.date=2016-07-13&rft.eissn=2166-1030&rft.volume=245&rft.spage=S40&rft_id=info:doi/10.1080%2F00365513.2016.1208446&rft_id=info%3Apmid%2F27542002&rft.externalDocID=27542002 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0036-5513&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0036-5513&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0036-5513&client=summon |